{"filings":[{"id":99362,"accession_number":"0000879407-26-000045","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 revenue $73.7M, net loss $0.93; REDEMPLO strong; $930M capital raise; Madrigal license","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $73.7M (down 86% YoY); net loss $132.7M ($0.93 diluted EPS) vs prior-year income $370.4M ($2.75 EPS).","REDEMPLO launch: >400 prescriptions, ~180 patients shipped, ~30 new scripts/week, 85% APOC3-naive patients.","Licensed ARO-PNPLA3 to Madrigal for $25M upfront, up to $975M milestones, tiered royalties (high-single to mid-teens).","Raised $930M: $700M zero-coupon converts due 2032 (35% premium) and $230M stock at $64.50/sh.","Obesity: ARO-INHBE combo -9.4% weight loss wk16 (vs -4.8%); ARO-ALK7 -88% mRNA knockdown, -14.1% visceral fat."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":337770000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115315,"accession_number":"0000879407-26-000037","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Arrowhead say-on-pay proposal fails at 2026 annual meeting; director Michael Perr receives 31% against votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Say-on-pay proposal failed: 41.6M for, 60.0M against, 17.9M broker non-votes.","Director Michael Perr received 31.3M against votes (70.4M for), highest dissent of any nominee.","Amended 2021 Incentive Plan approved: 99.2M for, 2.4M against, 0.3M abstain.","KPMG ratified as auditor for FY2026: 119.1M for, 0.4M against, 0.4M abstain.","All other directors elected with over 90% support from votes cast (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115314,"accession_number":"0000879407-26-000033","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q1 revenue $264M; REDEMPLO launched; $930M financing closed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $264M (vs $2.5M YoY); net income $30.8M ($0.22 diluted EPS) vs loss $173M.","REDEMPLO FDA-approved for FCS; over 100 prescriptions received since US launch.","Closed $930M public offerings: $0% convertible notes due 2032 + stock at $64.50/sh.","Novartis collaboration for ARO-SNCA: $200M upfront, up to $2B milestones, royalties.","Obesity candidate ARO-INHBE + tirzepatide achieved -9.4% weight loss at week 16."],"consensus_eps_estimate":null,"consensus_eps_actual":0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":264033000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115313,"accession_number":"0001193125-26-010582","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Arrowhead issues $700M zero-coupon convertible notes due 2032; enters capped call to reduce dilution","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Arrowhead issued $700M 0.00% convertible senior notes due 2032; conversion price ~$87.07 per share.","Entered capped call transactions costing ~$47.9M to reduce potential dilution from conversion.","Underwriters' over-allotment option of $75M fully exercised; total notes issued $700M.","Notes mature Jan 15, 2032; no regular interest; special interest up to 0.50% for reporting failures.","Initial conversion rate 11.4844 shares per $1,000 principal; redeemable after Jan 16, 2029 under conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115312,"accession_number":"0001193125-26-007971","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Arrowhead prices upsized $625M zero-coupon convertible notes and $216.6M equity offering","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Net proceeds of ~$681.3M from $700M (including over-allotment) of 0.00% convertible notes due 2032.","Net proceeds of ~$216.6M from equity offering: 3.1M shares at $64.50 plus pre-funded warrants for 1.55M shares.","Notes convertible at initial price of ~$87.07 (35% premium); capped call transactions entered to reduce dilution.","Proceeds for general corporate purposes, R&D, commercialization, and potential prepayment of Sixth Street credit facility.","Offerings priced Jan 7, 2026; equity closes Jan 9, notes close Jan 12, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115311,"accession_number":"0000879407-26-000004","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Arrowhead reports Phase 1/2a data: ARO-INHBE + tirzepatide doubles weight loss in obese T2DM patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARO-INHBE + tirzepatide (n=4) achieved -9.4% weight loss at week 16 vs -4.8% with tirzepatide alone; visceral fat -23.2% vs -7.4%.","ARO-INHBE monotherapy: single dose reduced visceral fat -9.9% at week 16; two doses gave -15.6% placebo-adjusted at week 24.","ARO-ALK7 is first RNAi to silence an adipocyte gene; mean ALK7 mRNA reduction -88% at 200 mg; visceral fat -14.1% at week 8.","Both candidates generally well tolerated; no discontinuations; one unrelated SAE (limb abscess) in ARO-INHBE group.","Company expects additional results from these ongoing Phase 1/2a studies later in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131731,"accession_number":"0000879407-25-000027","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead FY2025 revenue $829M on milestones; FDA approves first drug REDEMPLO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $829.4M in FY2025, up from $3.6M, driven by Novartis and Sarepta milestone payments.","FDA approved REDEMPLO (plozasiran) for FCS—first approved siRNA for the rare disease; self-administered quarterly.","Novartis licensing agreement for ARO-SNCA: $200M upfront, up to $2B milestones, low double-digit royalties.","Sarepta paid $300M milestones; $100M settled with cash and Arrowhead stock buyback at $18.79 per share.","Net loss attributable to Arrowhead: ($1.6M) vs ($599M) prior year; cash resources $919.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":829448000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131730,"accession_number":"0000879407-25-000019","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO for Familial Chylomicronemia Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["REDEMPLO (plozasiran) approved by FDA as adjunct to diet to reduce triglycerides in adults with FCS.","Phase 3 PALISADE study showed 80% median triglyceride reduction vs 17% placebo and lower acute pancreatitis incidence.","REDEMPLO is first FDA-approved siRNA medicine for FCS, self-administered quarterly at home.","Approximately 6,500 people in the U.S. live with genetic or clinical FCS.","Arrowhead's first FDA-approved medicine marks transition to a commercial-stage company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148307,"accession_number":"0000879407-25-000010","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ionis sues Arrowhead for patent infringement over plozasiran, threatening FCS launch","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Ionis filed complaint in Central District of California alleging Arrowhead's plozasiran infringes U.S. Patent No. 9,593,333.","Arrowhead had preemptively sought declaratory judgment in Delaware to invalidate the same patent on Sept. 10, 2025.","Arrowhead expects FDA decision on plozasiran NDA by Nov. 18, 2025 (PDUFA) and plans Q4 2025 launch.","The '333 patent covers method of reducing triglycerides in adults with familial chylomicronemia syndrome (FCS).","Ionis says it sent a pre-suit notice on Sept. 3, 2025; Arrowhead did not engage before filing DJ action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148306,"accession_number":"0000879407-25-000007","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Arrowhead files declaratory judgment suit against Ionis over '333 patent for plozasiran","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Arrowhead filed a declaratory judgment action in Delaware against Ionis claiming the '333 patent is invalid and not infringed by plozasiran.","Plozasiran is Arrowhead's RNAi therapy for familial chylomicronemia syndrome (FCS); Phase 3 PALISADE study showed up to 80% triglyceride reduction.","FDA PDUFA action date for plozasiran is November 18, 2025.","Ionis sent a September 3, 2025 letter alleging patent infringement and threatening suit; Arrowhead acted preemptively.","Arrowhead's complaint alleges the '333 patent claims are invalid for anticipation and lack of written description/enablement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148305,"accession_number":"0000879407-25-000004","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Arrowhead licenses ARO-SNCA to Novartis for $200M upfront, up to $2B milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Arrowhead receives $200M upfront; eligible for up to $2B in development, regulatory, sales milestones.","Novartis gets exclusive worldwide license to preclinical ARO-SNCA (siRNA for synucleinopathies like Parkinson's).","Arrowhead will complete preclinical work; Novartis handles clinical development, manufacturing, commercialization.","Arrowhead eligible for tiered royalties up to low double digits on net product sales.","Transaction expected to close H2 2025, subject to HSR antitrust clearance and customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148304,"accession_number":"0001628280-25-038867","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).","Cash & securities $900.4M; credit facility $240.3M; liability from royalty sale $360.3M.","Sanofi to pay Visirna $130M upfront for Greater China license to plozasiran; up to $265M milestones.","Earned $100M milestone from Sarepta; second enrollment target for ARO-DM1 may trigger $200M by end-2025.","Plozasiran NDA accepted with PDUFA date Nov 18, 2025; Phase 3 SHASTA-3/4 and MUIR-3 fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":0.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":572976000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167087,"accession_number":"0001628280-25-024675","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 revenue $542.7M on Sarepta deal; plozasiran PDUFA Nov 18, 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue of $542.7M (vs $0 prior year) driven by $825M Sarepta licensing deal ($500M cash + $325M equity).","GAAP diluted EPS $2.75 vs ($1.02) loss YoY; net income $370.4M.","FDA accepted plozasiran NDA for FCS with PDUFA date Nov 18, 2025; no advisory committee planned.","CFO Ken Myszkowski retiring May 13, 2025; succeeded by Daniel Apel.","Cash and investments $1.097B; company funded into 2028 with no near-term equity needs."],"consensus_eps_estimate":-1.0456,"consensus_eps_actual":1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":545209000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167086,"accession_number":"0001628280-25-017844","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead CFO Ken Myszkowski to retire May 13; Daniel Apel named new CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Myszkowski will retire as CFO effective May 13, 2025, after 16 years; no disagreement cited.","Daniel Apel, former Global Head of FP&A at Walgreens Boots Alliance and Bayer US CFO, appointed CFO same date.","Apel receives $575K base salary, 45% target bonus, 100K RSUs vesting over 4 years, and up to $200K relocation.","Myszkowski will serve as adviser through Jan 31, 2026, at $200K annual salary with continued benefits and equity vesting.","CEO cites transition to commercial stage with planned plozasiran launch pending regulatory review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184454,"accession_number":"0001628280-25-013619","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Arrowhead shareholders elect eight directors, approve executive compensation, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected with majority support; Douglas Ingram received 68.9M for vs 13.8M against.","Advisory vote to approve executive compensation passed with 75.3M for, 7.4M against.","Advisory vote on frequency of future say-on-pay selected 1 year with 79.9M votes.","Ratification of KPMG as independent auditors approved with 101.0M for, 1.2M against.","Over 102.7M shares voted out of 125.1M outstanding; all proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184453,"accession_number":"0001628280-25-004637","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q1 net loss $173M; $825M Sarepta deal & plozasiran NDA accepted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $173M ($1.39 diluted EPS), revenue $2.5M, operating loss $161.4M.","Sarepta collaboration: $825M upfront ($500M cash + $325M equity at $27.25/share, 35% premium), plus $250M over 5 years, up to $10B milestones.","Plozasiran NDA for familial chylomicronemia syndrome accepted; PDUFA date Nov 18, 2025.","Phase 3 PALISADE met primary endpoint; plozasiran reduced triglycerides up to 86% and acute pancreatitis.","Cash & investments $552.9M; company funded into 2028; obesity programs (ARO-INHBE, ARO-ALK7) entering Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":2500000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184452,"accession_number":"0001628280-25-004313","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead appoints Sarepta CEO Douglas Ingram as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas Ingram appointed to Arrowhead board effective Feb 6, 2025, per Investor Rights Agreement with Sarepta.","Ingram is President and CEO of Sarepta, with which Arrowhead has a collaboration agreement from Nov 2024.","He receives standard non-employee director compensation plus sign-on RSUs of $771,200 vesting over 3 years.","Ingram is not independent under Nasdaq rules due to the Sarepta collaboration and stock purchase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201045,"accession_number":"0001628280-24-051729","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead Chairman Dr. Given to retire; Sarepta CEO Ingram expected to join board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Douglass Given retires from Board effective Dec 31, 2024, after 14 years as Chairman.","Douglas S. Ingram, President and CEO of Sarepta Therapeutics, expected to join Board in Q1 2025.","Ingram's appointment aligns with closing of Arrowhead-Sarepta Exclusive License and Collaboration Agreement (Nov 25, 2024).","Company expresses gratitude for Dr. Given's service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201044,"accession_number":"0001628280-24-049281","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.","Revenue fell to $3.55M from $240.7M, primarily due to lower collaboration revenue.","Signed licensing deal with Sarepta: $825M upfront ($500M cash, $325M equity), plus $250M over 5 years.","Closed $500M senior secured credit facility with Sixth Street; $400M funded at close.","Submitted NDA for plozasiran (FCS) and received Breakthrough Therapy designation from FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217055,"accession_number":"0001628280-24-036113","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q3 net loss $170.8M ($1.38/sh); secures $500M credit facility; plozasiran Phase 3 meets endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $170.8M ($1.38 diluted EPS) vs $102.9M ($0.96) a year ago; revenue nil vs $15.8M.","Secured $500M non-dilutive credit facility from Sixth Street ($400M funded, $100M available) plus $50M milestone from Royalty Pharma.","Pivotal Phase 3 PALISADE study of plozasiran in FCS met primary endpoint: triglycerides reduced up to 80%, APOC3 up to 94%, acute pancreatitis incidence reduced vs placebo.","Initiated Phase 3 SHASTA-3/4 for plozasiran in severe hypertriglyceridemia; plans for Phase 3 CAPITAN cardiovascular outcomes trial.","Cash and investments $436.7M at June 30, 2024, up from $403.6M at Sept 30, 2023; company approaching plozasiran launch in 2025 if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236824,"accession_number":"0001628280-24-022233","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Arrowhead Q2 net loss $125.3M ($1.02/share) vs prior year net income $48.7M; revenue $0","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $125.3 million ($1.02 diluted loss per share) compared to net income of $48.7 million ($0.45 diluted EPS) in Q2 2023.","Revenue was $0, down from $146.3 million a year ago, with no milestone or collaboration revenue recorded.","R&D expenses rose to $101.1 million from $74.9 million; cash and investments totaled $523.1 million, boosted by $450 million stock offering.","Received $50 million milestone from Royalty Pharma in Q3 for olpasiran Phase 3 enrollment completion (Amgen-conducted trial).","Positive Phase 2 SHASTA-2 plozasiran data: 90.6% of patients achieved triglycerides <500 mg/dL at week 24."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":3551000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254435,"accession_number":"0001628280-24-011930","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Arrowhead shareholders elect 7 directors, approve exec pay, ratify KPMG at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All seven director nominees elected; votes for ranged from 76.4M (Given) to 84.3M (Anzalone), with ~19.3M broker non-votes.","Advisory vote on executive compensation passed with 82.6M for, 4.95M against, 143k abstain.","Ratification of KPMG as independent auditor for FY2024 passed with 104.1M for, 2.6M against, 366k abstain.","Record date Jan 19, 2024; 106.99M of 123.84M shares voted at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254430,"accession_number":"0001628280-24-011557","cik":879407,"company_name":"ARROWHEAD PHARMACEUTICALS, INC.","ticker":"ARWR","form_type":"8-K/A","filed_at":"2024-03-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Arrowhead appoints Hongbo Lu to board; board expands to eight, effective March 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hongbo Lu appointed to Arrowhead Board; board expanded from seven to eight, effective March 15, 2024.","Dr. Lu receives sign-on RSU grant of $761,666, vesting over three years.","Dr. Lu will receive standard non-employee director compensation as described in the 2024 proxy statement.","Dr. Lu has no family relationships with executives and no material interest in any related-party transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":11126295254.234747,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}